Ultragenyx Pharmaceutical Inc. (RARE) saw a big move last session, as the company’s shares fell by nearly 12% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for RARE, as the stock is now up around 9.4% in the past one-month time frame.
This slump shouldn’t be too much of a surprise to investors, as though the development-stage biotechnology company has seen no negative revision in the past few weeks, its current year loss consensus has widened over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
RARE currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the Biomedical industry include Actelion Ltd. (ALIOF), Biogen Idec Inc. (BIIB) and Curis, Inc. (CRIS). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ULTRAGENYX PHARMACEUTICAL INC (RARE): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
CURIS INC (CRIS): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Personal Investing Ideas & Strategies